Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Urologic Oncology
In which patients are referring for focal gland therapy for localized prostate cancer?
Do you prefer HIFU or cryoablation? Do you use in newly diagnosed or post-RT recurrence, or both?
Related Questions
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
What chemotherapy regimen do you use for de novo metastatic squamous cell carcinoma of penile urethra?
What are your top takeaways in GU Cancers from ESMO 2025?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
What are your top takeaways from ASCO GU 2025?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
In patients with NCCN-defined very high risk localized prostate adenocarcinoma who have a contraindication to abiraterone plus prednisone, do you consider starting ARPI (such as enzalutamide) instead, in addition to ADT?
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
Is there any evidence that ivermectin suppresses the PSA level in prostate cancer?